All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...
As part of Arvinas global collaboration with Pfizer, the companies plan to: Announce topline data for the VERITAC-2 Phase 3 monotherapy cli ...
Employees are now largely left to their own devices to figure out the benefits enrollment process. This “passive enrollment” ...
Mild electrical brain stimulation did not further improve motor recovery in stroke survivors, according to late-breaking science presented today at the American Stroke Association's International ...
A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...
Hosted on MSN5d
Amgen Earnings Transcript (NASDAQ:AMGN)Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...
IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced ...
Surveys are an important tool to determine actions for improvement. This year, the UAB community will have several ...
The "Candidiasis - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report includes an overview of trial numbers and their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback